{"id":3116,"date":"2024-06-10T11:22:25","date_gmt":"2024-06-10T15:22:25","guid":{"rendered":"https:\/\/cytel.agencyukdev.com\/perspectives\/accelerating-development-with-combined-sad-mad-approach\/"},"modified":"2024-08-21T10:58:17","modified_gmt":"2024-08-21T14:58:17","slug":"accelerating-development-with-combined-sad-mad-approach","status":"publish","type":"perspectives","link":"https:\/\/cytel.agencyukdev.com\/fr\/perspectives\/accelerating-development-with-combined-sad-mad-approach\/","title":{"rendered":"Accelerating Development with Combined SAD\/MAD Approach"},"content":{"rendered":"

 <\/p>\n

Single ascending dose (SAD) and multiple ascending dose (MAD) studies are typically the first in human studies.\u00a0 They seek to gain information on safety and tolerability, general pharmacokinetic (PK) and pharmacodynamic ( PD) \u00a0<\/em>characteristics, and of course identify the maximum tolerated dose (MTD).<\/p>\n

Conventionally, SAD \u00a0and MAD studies were conducted separately, but increasingly are combined into an “umbrella” protocol which addresses both SAD and MAD objectives.<\/p>\n

<\/p>\n

This approach can result in both time and cost savings and allow additional valuable information to be gained earlier and inform subsequent development. \u00a0When the studies are designed as a combined approach, adaptive principles are used as decisions will be made mid-study to adjust the dose, change the number of subjects receiving a certain dose, or stop a treatment entirely.<\/p>\n

In one recent project, we provided early phase trial design and biostatistics operational support\u00a0for our client, an emerging biopharma with an early phase pipeline of products in neurological indications.<\/p>\n

 <\/p>\n

Challenge<\/strong><\/p>\n

With a constrained budget, and minimal infrastructure our client wanted an operationally efficient solution for a first-in-human study and day to day support from an expert team who would require minimal oversight.<\/p>\n

 <\/p>\n

Solution<\/strong><\/p>\n

Cytel statistical consultants devised an adaptive maximizing SAD\/ MAD design combining multiple PK, PD, safety and tolerability objectives.<\/p>\n

To create the study design, the Cytel consultant used Cytel’s specialist Compass software which is dedicated to the design, simulation, and execution of early phase clinical trials. It provides a systematic and efficient way to investigate and compare conventional versus adaptive dose-finding designs.<\/p>\n

The below figure describes the structure of an example combined SAD\/MAD approach.<\/p>\n

 <\/p>\n

\"SADMAD\"<\/p>\n

 <\/p>\n

Cytel’s experienced biostatistics and statistical programming team went on to provide analysis and reporting services for the project.<\/p>\n

A SAD\/MAD trial can be followed by an\u00a0adaptive dose-finding trial\u00a0to identify and solidify evidence of dose(s) with target level(s) of response.<\/p>\n

 <\/p>\n

Value added<\/strong><\/p>\n

The trial has been designed to provide a solid understanding of dose tolerability and PK\/ PD measurements at doses with target levels of response.\u00a0 This enabled the client \u00a0to move forward with a good regulatory package which provides the FDA and EMA the best evidence of early phase drug effect.<\/p>\n

 <\/p>","protected":false},"featured_media":3470,"parent":0,"template":"","meta":{"_acf_changed":false},"tags":[76],"by-topic":[429,250],"by-year":[508],"class_list":["post-3116","perspectives","type-perspectives","status-publish","has-post-thumbnail","hentry","tag-blog","by-topic-adaptive-clinical-trials","by-topic-phase-1","by-year-508"],"acf":[],"yoast_head":"\nAccelerating Development with Combined SAD\/MAD Approach - Clinical Trial Software & Data Analysis | Cytel | Contact Us<\/title>\n<meta name=\"description\" content=\"Accelerating development with a combined SAD ( single ascending dose) \/ MAD ( Multiple ascending dose) design .\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.cytel.com\/perspectives\/accelerating-development-with-combined-sad-mad-approach\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Accelerating Development with Combined SAD\/MAD Approach - Clinical Trial Software & Data Analysis | Cytel | Contact Us\" \/>\n<meta property=\"og:description\" content=\"Accelerating development with a combined SAD ( single ascending dose) \/ MAD ( Multiple ascending dose) design .\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.cytel.com\/perspectives\/accelerating-development-with-combined-sad-mad-approach\/\" \/>\n<meta property=\"og:site_name\" content=\"Clinical Trial Software & Data Analysis | Cytel | Contact Us\" \/>\n<meta property=\"article:modified_time\" content=\"2024-08-21T14:58:17+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.cytel.com\/wp-content\/uploads\/2024\/05\/Cytel_web_abstract-06.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2048\" \/>\n\t<meta property=\"og:image:height\" content=\"1365\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data1\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.cytel.com\\\/perspectives\\\/accelerating-development-with-combined-sad-mad-approach\\\/\",\"url\":\"https:\\\/\\\/www.cytel.com\\\/perspectives\\\/accelerating-development-with-combined-sad-mad-approach\\\/\",\"name\":\"Accelerating Development with Combined SAD\\\/MAD Approach - Clinical Trial Software & Data Analysis | Cytel | Contact Us\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/cytel.agencyukdev.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.cytel.com\\\/perspectives\\\/accelerating-development-with-combined-sad-mad-approach\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.cytel.com\\\/perspectives\\\/accelerating-development-with-combined-sad-mad-approach\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cytel.agencyukdev.com\\\/wp-content\\\/uploads\\\/2024\\\/05\\\/Cytel_web_abstract-06.jpg\",\"datePublished\":\"2024-06-10T15:22:25+00:00\",\"dateModified\":\"2024-08-21T14:58:17+00:00\",\"description\":\"Accelerating development with a combined SAD ( single ascending dose) \\\/ MAD ( Multiple ascending dose) design .\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.cytel.com\\\/perspectives\\\/accelerating-development-with-combined-sad-mad-approach\\\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.cytel.com\\\/perspectives\\\/accelerating-development-with-combined-sad-mad-approach\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/www.cytel.com\\\/perspectives\\\/accelerating-development-with-combined-sad-mad-approach\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cytel.agencyukdev.com\\\/wp-content\\\/uploads\\\/2024\\\/05\\\/Cytel_web_abstract-06.jpg\",\"contentUrl\":\"https:\\\/\\\/cytel.agencyukdev.com\\\/wp-content\\\/uploads\\\/2024\\\/05\\\/Cytel_web_abstract-06.jpg\",\"width\":2048,\"height\":1365},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.cytel.com\\\/perspectives\\\/accelerating-development-with-combined-sad-mad-approach\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"https:\\\/\\\/cytel.agencyukdev.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Accelerating Development with Combined SAD\\\/MAD Approach\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/cytel.agencyukdev.com\\\/#website\",\"url\":\"https:\\\/\\\/cytel.agencyukdev.com\\\/\",\"name\":\"Clinical Trial Software & Data Analysis | Cytel | Contact Us\",\"description\":\"Innovative Trial Design. Cytel is the largest provider of statistical software and advanced analytics for clinical trial design and execution.\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/cytel.agencyukdev.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Accelerating Development with Combined SAD\/MAD Approach - Clinical Trial Software & Data Analysis | Cytel | Contact Us","description":"Accelerating development with a combined SAD ( single ascending dose) \/ MAD ( Multiple ascending dose) design .","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.cytel.com\/perspectives\/accelerating-development-with-combined-sad-mad-approach\/","og_locale":"fr_FR","og_type":"article","og_title":"Accelerating Development with Combined SAD\/MAD Approach - Clinical Trial Software & Data Analysis | Cytel | Contact Us","og_description":"Accelerating development with a combined SAD ( single ascending dose) \/ MAD ( Multiple ascending dose) design .","og_url":"https:\/\/www.cytel.com\/perspectives\/accelerating-development-with-combined-sad-mad-approach\/","og_site_name":"Clinical Trial Software & Data Analysis | Cytel | Contact Us","article_modified_time":"2024-08-21T14:58:17+00:00","og_image":[{"width":2048,"height":1365,"url":"https:\/\/www.cytel.com\/wp-content\/uploads\/2024\/05\/Cytel_web_abstract-06.jpg","type":"image\/jpeg"}],"twitter_card":"summary_large_image","twitter_misc":{"Dur\u00e9e de lecture estim\u00e9e":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.cytel.com\/perspectives\/accelerating-development-with-combined-sad-mad-approach\/","url":"https:\/\/www.cytel.com\/perspectives\/accelerating-development-with-combined-sad-mad-approach\/","name":"Accelerating Development with Combined SAD\/MAD Approach - Clinical Trial Software & Data Analysis | Cytel | Contact Us","isPartOf":{"@id":"https:\/\/cytel.agencyukdev.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.cytel.com\/perspectives\/accelerating-development-with-combined-sad-mad-approach\/#primaryimage"},"image":{"@id":"https:\/\/www.cytel.com\/perspectives\/accelerating-development-with-combined-sad-mad-approach\/#primaryimage"},"thumbnailUrl":"https:\/\/cytel.agencyukdev.com\/wp-content\/uploads\/2024\/05\/Cytel_web_abstract-06.jpg","datePublished":"2024-06-10T15:22:25+00:00","dateModified":"2024-08-21T14:58:17+00:00","description":"Accelerating development with a combined SAD ( single ascending dose) \/ MAD ( Multiple ascending dose) design .","breadcrumb":{"@id":"https:\/\/www.cytel.com\/perspectives\/accelerating-development-with-combined-sad-mad-approach\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.cytel.com\/perspectives\/accelerating-development-with-combined-sad-mad-approach\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.cytel.com\/perspectives\/accelerating-development-with-combined-sad-mad-approach\/#primaryimage","url":"https:\/\/cytel.agencyukdev.com\/wp-content\/uploads\/2024\/05\/Cytel_web_abstract-06.jpg","contentUrl":"https:\/\/cytel.agencyukdev.com\/wp-content\/uploads\/2024\/05\/Cytel_web_abstract-06.jpg","width":2048,"height":1365},{"@type":"BreadcrumbList","@id":"https:\/\/www.cytel.com\/perspectives\/accelerating-development-with-combined-sad-mad-approach\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Accueil","item":"https:\/\/cytel.agencyukdev.com\/"},{"@type":"ListItem","position":2,"name":"Accelerating Development with Combined SAD\/MAD Approach"}]},{"@type":"WebSite","@id":"https:\/\/cytel.agencyukdev.com\/#website","url":"https:\/\/cytel.agencyukdev.com\/","name":"Clinical Trial Software & Data Analysis | Cytel | Contact Us","description":"Innovative Trial Design. Cytel is the largest provider of statistical software and advanced analytics for clinical trial design and execution.","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/cytel.agencyukdev.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"}]}},"_links":{"self":[{"href":"https:\/\/cytel.agencyukdev.com\/fr\/wp-json\/wp\/v2\/perspectives\/3116","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cytel.agencyukdev.com\/fr\/wp-json\/wp\/v2\/perspectives"}],"about":[{"href":"https:\/\/cytel.agencyukdev.com\/fr\/wp-json\/wp\/v2\/types\/perspectives"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/cytel.agencyukdev.com\/fr\/wp-json\/wp\/v2\/media\/3470"}],"wp:attachment":[{"href":"https:\/\/cytel.agencyukdev.com\/fr\/wp-json\/wp\/v2\/media?parent=3116"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cytel.agencyukdev.com\/fr\/wp-json\/wp\/v2\/tags?post=3116"},{"taxonomy":"by-topic","embeddable":true,"href":"https:\/\/cytel.agencyukdev.com\/fr\/wp-json\/wp\/v2\/by-topic?post=3116"},{"taxonomy":"by-year","embeddable":true,"href":"https:\/\/cytel.agencyukdev.com\/fr\/wp-json\/wp\/v2\/by-year?post=3116"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}